期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 24, 期 8, 页码 1075-1082出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.2015.1058776
关键词
anti-CTLA-4; anti-PD1; cabozantinib; everolimus; hepatocellular carcinoma; immunotherapy; lenvatinib; oncolytic virus; ramucirumab; receptor tyrosine kinase inhibitor; refametinib; regorafenib; sorafenib; tivantinib; trebananib
资金
- Bayer Healthcare
- Novartis
Introduction: Sorafenib is the only systemic drug approved for the treatment of advanced hepatocellular carcinoma (HCC). Within recent years, several investigational agents mainly targeting angiogenesis failed in late-phase clinical development either due to toxicity or lack of benefit. Areas covered: This review covers recent clinical data on systemic agents and ongoing trials in patients with advanced HCC. Expert opinion: In unselected patients with advanced HCC, disappointing results have been reported from several large trials. However, in two subgroups encouraging results have been achieved. Treatment with the MET inhibitor tivantinib resulted in a substantial survival benefit in the subgroup of MET overexpressing tumors in a randomized Phase II trial. Furthermore, the vascular endothelial growth factor receptor 2 antibody rannucirumab resulted in improved overall survival in patients with baseline alpha-fetoprotein (AFP) >= 400 ng/ml in a Phase III trial. These two agents, and several others, will be further developed in HCC. Moreover, immunotherapeutics such as checkpoint inhibitors, programmed death receptor-1 blocking antibodies and oncolytic viruses are under investigation in advanced HCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据